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che Erkrankung bei Kaniden und anderen Karnivoren. Spätestens seit dem Löwen-Massensterben 1994
im Serengeti Nationalpark in Tanzania ist allgemein bekannt, dass auch Feliden infiziert werden können.
Im Gegensatz zur Situation bei den Grosskatzen ist die Bedeutung der Staupeinfektion bei Hauskatzen
aber grösstenteils unbekannt. In in vitro Versuchen konnten wir zeigen, dass sich der Staupevirusstamm
A75/17 gleich gut in Hunde- wie auch in Katzen-Lymphozyten vermehrt. In diesem Zusammenhang
haben wir den Morbillivirus-Rezeptor SLAM (Signaling Lymphocyte Activation Molecule), der zuvor
erst in anderen Spezies bekannt war, mittels PCR neu auch in Katzen-Lymphozyten nachgewiesen.
In einem zweiten Schritt wurden ein indirekter Immunfluoreszenz und ein Western-Blot Test für die
schnelle Erkennung von CDV-spezifischen Antikörpern in Katzenseren entwickelt. Antikörper gegen das
Hämagglutinin- und Nukleokapsid-Protein vom Staupevirusstamm A75/17 existierten sowohl in Blut-
proben von Hauskatzen aus der Schweiz (10/500, 2%), wie auch aus Spanien (8/97, 8.2%) und den Vere-
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sehr kleiner Anteil der seropositiven Katzen hatte auch virusneutralisierende Antikörper gegen A75/17
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muss deshalb in weiteren Studien untersucht werden. Canine distemper virus (CDV) causes fatal disease
in many species of carnivores, including felids. In contrast to the situation in large felids, the impor-
tance of CDV infection in domestic cats remains largely unknown. In this study, we showed that CDV
strain A75/17 replicated as efficiently in feline as in canine peripheral blood mononuclear cells in vitro.
The presence of the morbillivirus receptor signaling lymphocyte activation molecule (SLAM) was demon-
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1 Zusammenfassung 
Das Staupevirus (Canine distemper virus, CDV) verursacht eine 
schwerwiegende multisystemische Erkrankung bei Kaniden und anderen 
Karnivoren. Seit dem Löwen-Massensterben 1994 im Serengeti Nationalpark 
in Tansania ist unumstritten, dass auch Feliden infiziert werden können. Im 
Gegensatz zur Situation bei den Grosskatzen ist die Bedeutung der 
Staupeinfektion bei Hauskatzen aber grösstenteils unbekannt. In in vitro 
Versuchen konnten wir zeigen, dass sich der Staupevirusstamm A75/17 gleich 
gut in Hunde- wie auch in Katzen-Lymphozyten vermehrt. In diesem 
Zusammenhang haben wir den Morbillivirus-Rezeptor SLAM (Signaling 
Lymphocyte Activation Molecule), der zuvor erst in anderen Spezies bekannt 
war, mittels PCR neu auch in Katzen-Lymphozyten nachgewiesen. In einem 
zweiten Schritt wurden ein indirekter Immunfluoreszenz und ein Western-Blot 
Test für die schnelle Erkennung von CDV-spezifischen Antikörpern in 
Katzenseren entwickelt. Antikörper gegen das Hämagglutinin- und 
Nukleokapsid-Protein vom Staupevirusstamm A75/17 existierten sowohl in 
Blutproben von Hauskatzen aus der Schweiz (10/500, 2%), wie auch aus 
Spanien (8/97, 8.2%) und den Vereinigten Arabischen Emiraten (17/93, 
18.3%). In den beiden letzteren Ländern war der Anteil an Katzen mit 
Antikörpern gegen CDV in der FIV (Felines Immunschwäche Virus)-
seropositiven Population signifikant grösser als in der FIV-seronegativen 
Population (P = 0.0001). Es wurde jedoch kein Zusammenhang zwischen der 
Seropositivität und dem Auftreten von klinischen Symptomen gefunden. Nur 
ein sehr kleiner Anteil der seropositiven Katzen hatte auch 
virusneutralisierende Antikörper gegen A75/17 und/oder den Onderstepoort 
CDV-Stamm. Von den 72 getesteten Grosskatzen aus europäischen Zoos 
wiesen 7 gesunde ungeimpfte Tiere Antikörper gegen Staupe auf, 2 davon 
auch virusneutralisierende. Zusammenfassend lässt sich sagen, dass die 
Staupevirusinfektion bei Katzen weit verbreitet ist ohne zu klinischer 
 2 
Symptomatik zu führen. Die Rolle der Hauskatze als Träger des Staupevirus 
muss deshalb in weiteren Studien untersucht werden. 
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2 Summary 
Canine distemper virus (CDV) causes fatal disease in many species of 
carnivores, including felids. In contrast to the situation in large felids, the 
importance of CDV infection in domestic cats remains largely unknown. In this 
study, we showed that CDV strain A75/17 replicated as efficiently in feline as 
in canine peripheral blood mononuclear cells in vitro. The presence of the 
morbillivirus receptor signaling lymphocyte activation molecule (SLAM) was 
demonstrated by PCR in feline cells. An indirect immunofluorescence and a 
Western blot assay were established for the rapid detection of CDV-specific 
antibodies in cat sera. Antibodies against the hemagglutinin and nucleocapsid 
proteins of CDV strain A75/17 were present in domestic cats from Switzerland 
(10/500, 2%), Spain (8/97, 8.2%) and the United Arab Emirates (17/93, 
18.3%). The frequency of CDV seropositive cats in Spain and the United Arab 
Emirates was significantly higher in the feline immunodeficiency virus (FIV) 
seropositive population than in FIV negative cats (P = 0.0001). No clinical 
signs were found in most CDV seropositive cats. Antibodies neutralizing 
A75/17 and/or the Onderstepoort strain of CDV were found in only a small 
proportion of seropositive cats. Among the 72 tested captive large felids from 
Europe, 7 healthy non-vaccinated animals were found to be CDV seropositive 
and 2 of them had also virusneutralizing antibodies. Based on these data, we 
conclude that CDV infection in domestic cats is widespread, although the 
infection remains subclinical. Therefore, the role of the domestic cat as a 
carrier of CDV needs to be further investigated. 
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3 Introduction 
Canine distemper virus (CDV), a member of the genus Morbillivirus of 
the family Paramyxoviridae, causes serious multisystemic disease in canids 
worldwide (5). Due to regular vaccination with modified live virus vaccines, the 
incidence of clinical distemper in domestic dogs has decreased considerably 
during the last decades. However, several outbreaks of the disease, also in 
vaccinated dogs, raised questions about the efficacy of the vaccines (8, 13, 
16, 25). In addition, CDV has a broad host range, which makes eradication 
nearly impossible. CDV infections have been diagnosed in terrestrial and 
marine mammals worldwide (7). Members of all families of terrestrial 
carnivores were shown to be susceptible to the infection: Canidae, Mustelidae, 
Hyaenidae, Procyonidae, Ursidae, Viverridae and also Felidae (12). 
In 1994, CDV caused an unexpected mass mortality in the lion 
population of the Serengeti National Park in Tanzania, resulting in the death of 
around 1000 lions (29). Earlier reports of clinical distemper in captive large 
felids in the United States (4, 9) and a retrospective study based on necropsy 
cases of captive lions and tigers in Switzerland (26) revealed that CDV 
infection in large felids has been present for a longer time and is more 
widespread than previously thought. However, the importance of CDV in 
domestic cats remains unclear. Specific-pathogen-free cats have been shown 
to be susceptible to experimental infection (2, 18). Interestingly, despite a 
slight increase in body temperature, no clinical signs were observed. A 
seroprevalence study carried out in the Asian countries Taiwan, Vietnam and 
Japan, indicated different prevalences of CDV-specific antibodies in domestic 
cats, varying from 0% to 88.8%, depending on the region studied and on 
exposure to dogs (19). Acutely infected dogs shed virus in all body excretions, 
regardless of clinical signs. The main route of transmission is via aerosol of 
respiratory secretions. Virus transmission from dogs to cats, but not vice 
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versa, was documented experimentally (2). There was no correlation between 
CDV seropositivity and the clinical status in the cats from Asia.  
The aim of this study was to determine the seroprevalence of antibodies 
to CDV in domestic cats in countries harbouring different population densities 
of feral dogs and cats and to possibly correlate these findings with the 
presence of circulating distemper in dogs. We were also interested in 
establishing an association between the seropositivity in cats and the 
existence of clinical signs of disease. In addition, in vitro infectivity assays 
were performed to compare the efficiency of CDV infection in feline and canine 
cells. Due to the fact that CDV readily replicated in feline peripheral blood 
mononuclear cells, the feline analogue of the signaling lymphocyte activation 
molecule (SLAM), a morbillivirus receptor, was identified and partly 
sequenced. A better understanding of the CDV infection in domestic cats may 
be an important aspect for the health management of both cats and dogs as 
cats could either be affected by the disease themselves or play a role as 
carriers. 
 
4 Materials and Methods 
4.1 Cells and virus strains 
Vero cells were grown in cell culture medium (RPMI-1640, Sigma-
Aldrich, Buchs, Switzerland) supplemented with 10% heat-inactivated fetal calf 
serum (FCS, BioConcept, Allschwil, Switzerland), 2 mM L-glutamine (Gibco, 
Eggenstein, Germany), 100 units/ml penicilline G, 100 µg/ml streptomycin and 
0.25 µg/ml amphotericine B (Gibco). Peripheral blood mononuclear cells 
(PBMC) were isolated from freshly collected blood of specific-pathogen-free 
(SPF) dogs and cats. Cats originated from Liberty Research (Waverly, NY) 
and dogs from RCC Ltd (Füllinsdorf, Switzerland). The blood collection was 
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carried out by venipuncture using K3-EDTA-anticoagulated vacutainers. 
PBMCs were isolated by Ficoll gradient centrifugation (Histopaque-1077, 
Sigma-Aldrich) and grown in cell culture medium mentioned above, 
supplemented with 1 mM β-mercaptoethanole and 10 µg/ml concanavalin A 
(both Sigma-Aldrich). After 24 h 100 units/ml of human interleukin-2 (kindly 
provided by Novartis AG, Basel, Switzerland) were added and used for all 
further medium replacements. 
The Onderstepoort (OP) CDV vaccine strain was propagated in Vero 
cells, using techniques described by Appel and Robson (1), with the following 
modifications: Vero cells were inoculated at 70 – 80% confluency with 5 ml of 
virus suspension containing 104 tissue culture infectious dose 50 (TCID50) in 
75 cm2 cell culture flasks. After virus adsorption for 2 h at 37°C, 15 ml of cell 
culture medium supplemented with 2% FCS was added per flask and cultures 
were incubated until a pronounced cytopathic effect was observed. The 
virulent strain A75/17 from lymphoid tissue of experimentally infected dogs 
(11) was passaged once in PBMCs from a SPF dog as previously described 
(3) before using for infection. 
 
4.2 Infection of feline PBMCs with A75/17 
Supernatant of A75/17 infected canine lymphocytes was centrifuged for 
10 min at 2000 x g and diluted 1:4, 1:16, 1:64 and 1:256 with RPMI-1640. Two 
hundred microliters of each dilution were used for inoculation of 106 PBMCs 
collected from either a SPF dog or a SPF cat using a 24-well plate. 
Additionally, 200 µl of each dilution were cultured without cells and used as 
„virus only“ control. Uninfected cells were cultured in parallel as negative 
controls. One hour after infection, 800 µl of fresh medium was added to each 
well. Two hundred and fifty microliters of each cell-suspension were collected 
daily and replaced by fresh cell culture medium. Infected and non-infected 
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PBMC were analyzed by indirect immunofluorescence assay (IFA) and the 
supernatants were tested for the presence of CDV-RNA by real time TaqMan 
reverse transcriptase polymerase chain reaction (RT-PCR) on days 1, 2, 3, 4, 
6, 8 and 10 post-inoculation. For this purpose, total RNA was isolated from 
200 µl of supernatant using MagNaPure LC Total Nucleic Acid Isolation Kit 
(Roche Diagnostics, Rotkreuz, Switzerland) according to the manufacturer’s 
recommendations and RT-PCR was performed with a primer set specific for 
the morbillivirus polymerase gene as previously described (6). PCR was run 
for 45 cycles and reactions giving no positive fluorescence signal after 45 
cycles were judged negative. 
 
4.3 Cloning and sequencing of the feline signaling lymphocyte 
activation molecule (SLAM) 
Total RNA was isolated from 106 feline infected PBMCs (see above) 
using the RNeasy Mini Kit (Qiagen, Hombrechtikon, Switzerland) according to 
the manufacturer’s protocol. 
Based on consensus sequences from human, bovine and canine SLAM 
degenerated primers were designed to amplify a 458 bp-long stretch of the 
gene. The forward primer cwSLAM.427f 5’-GCT YTA TGA RCA GGT CTC 
CAC TCC-3’ and the reverse primer cwSLAM.884r 5’-TCT GGA CTT GGG 
CAT AGA TVG TAA G-3’ were used to amplify 5 µl of RNA using the 
SuperScript™ III One-Step RT-PCR System (Invitrogen, Basel, Switzerland), 
0.2 µM of each primer, in a total volume of 25 µl. PCR cycling conditions were 
as follows: 30 min at 60°C (RT step), 2 min at 94°C, 40 cycles of 15 sec at 
94°C (denaturation), 30 sec at 50°C (annealing) and 1 min at 68°C 
(extension), followed by 5 min at 68°C. 
The resulting PCR band was analyzed on 2% agarose gels; the 
amplicon was purified using the MinElute Gel Extraction Kit (Qiagen). The 
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purified PCR product was cloned into the TOPO TA™ cloning vector 
(Invitrogen). The clonal DNA was checked for insert by digesting the DNA with 
the restriction enzyme EcoRI. Positive clones were then sequenced from both 
sides. Cycle sequencing was performed with approximately 20 ng of DNA and 
3.3 pmol plasmid-specific primers using the BigDye Terminator Cycle 
Sequencing Ready Reaction Kit v1.1 (Applied Biosystems, Rotkreuz, 
Switzerland). Cycling conditions were as follows: 1 min at 96°C, then 25 cycles 
at 96°C for 10 sec and 50°C for 5 sec, followed by 60°C for 4 min. Products 
were purified using the DyeEx Spin column (Qiagen), and analyzed on the ABI 
Prism 310 Genetic Analyzer (Applied Biosystems). The sequences of two 
independent clones were aligned to one consensus sequence by SeqScape 
(Version 1.1, Applied Biosystems) and then compared to reference sequences 
deposited in the genebank. 
 
4.4 Immunization of two cats with an OP-mlv-vaccine 
To produce antibodies to CDV as positive control 2 one-year old cats 
were immunized subcutaneously three times with two weeks intervals using a 
commercially available OP modified-live virus vaccine (Vetamun Standard, 
Veterinaria, Zurich, Switzerland). Blood was collected twice a week and 
analysed for the presence of both CDV RNA by real time RT-PCR and 
antibodies by IFA. The serum collected at week three after the last vaccination 
was used as a positive control for the immunofluorescence and Western blot 
assays. 
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4.5 Serum samples 
Serum samples collected from Swiss domestic cats (n = 500) consisted 
of 208 samples of healthy and 292 samples of ill cats, which were collected at 
clinical practices and animal shelters between June and September 1996 or at 
the Veterinary Hospital of the Vetsuisse Faculty, University of Zurich, 
Switzerland in 2005. Samples of Spanish domestic cats (n = 97) were 
collected in 2005 at animal shelters, clinical practices and the Madrid zoo, 
where many feral cats live inside the zoo facilities. The samples originating 
from the United Arab Emirates (n = 93) were obtained from feral cats, captured 
in Abu Dhabi in 1999 in the context of a project for public health management. 
Serum samples originating from captive large felids (n = 72) were 
collected from healthy and ill lions (Panthera leo, n = 21), tigers (Panthera 
tigris, n = 22), ligers (Panthera leo x tigris, n = 2), leopards (Panthera pardus, 
n = 9), snow leopards (Uncia uncia, n = 11) and clouded leopards (Neofelis 
nebulosa, n = 7) between January 2001 and August 2005 in Switzerland, 
Germany and Austria. 
 
4.6 Indirect immunofluorescence assay 
Vero cells expressing the nucleocapsid (N) protein of A75/17 were used 
to establish an indirect IFA. Subconfluent Vero cells were transfected with the 
eukaryotic expression plasmid pCI (Promega, Wallisellen, Switzerland) 
containing the cDNA of the CDV N protein (11) using Lipofectamine 2000 
reagent (Invitrogen, Carlsbad, CA) as recommended by the manufacturer. 
Cells were trypsinized after 48 h, washed with 1x HBSS (Gibco), spotted onto 
12-well glass slides and air-dried. Onto every second well, non-transfected 
cells were spotted as a negative control. After fixation of the cells with ice-cold 
acetone the slides were stored at -20°C until use. 
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Cat serum samples were diluted 1:20 in phosphate-buffered saline 
(PBS, 150 mM NaCl, 8 mM Na2HPO4, 2 mM NaH2PO4, pH 7.4). Fifteen 
microliters of each sample were placed onto a well with either transfected or 
non transfected cells and the slides were incubated for 1 h at 37°C in a 
moisturized chamber. The slides were subsequently washed three times with 
PBS. Fluorescein isothiocyanate (FITC)-conjugated goat anti-cat IgG (Jackson 
ImmunoResearch, Cambridgeshire, UK) was diluted in PBS (1:400) and used 
as a secondary antibody. After 1 h of incubation at 37°C the slides were again 
washed three times with PBS and Vectashield Mounting Medium with DAPI 
(4’,6-Diamidino-2-phenylindole, Vector Laboratories, Burlingame, CA) to 
counterstain the DNA was used for embedding. The slides were examined 
under a fluorescence microscope and serum samples, which resulted in a 
fluorescent signal with the transfected but not with the non transfected cells, 
were considered positive for the presence of antibodies specific for the 
N protein of CDV or related morbilliviruses. 
 
4.7 Western blot analysis 
For antigen production canine PBMCs infected with the CDV strain 
A75/17 were cultured for 3 weeks in 1 L of cell culture medium as mentioned 
above. Cells were removed by centrifugation at 6'000 x g for 20 min. After 
careful harvesting of the cell culture supernatant, the virus was pelleted by 
centrifugation (160'000 x g, 50 min) using a Sorvall T647.5 rotor and 
resuspended in 5 ml TNE-buffer (10 mM Tris, 100 mM NaCl, 1 mM EDTA, 
pH 7.5). This sample was again centrifuged for 4 h at 80'000 x g in a Sorvall 
AH629 rotor through a 20% (w/w) sucrose layer onto a cushion of 
60% (w/w) sucrose. The band at the interface was collected and virus was 
again pelleted by centrifugation as described above. All centrifugation steps 
were performed at 4°C. 
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The viral pellet was used for the preparation of the Western blot 
membranes. Viral proteins were fractionated by sodium dodecyl sulphate-
polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto 
nitrocellulose transfer membranes (22). Each gel also contained a protein 
standard (Precision Plus Protein Dual Color Standards, Bio-Rad, Hercules, 
CA). The membranes were cut into strips of 2 mm, which were incubated 
either with the monoclonal antibody (mAb) D110 specific for the nucleocapsid 
protein (1µg/ml) (10), XI-23 specific for the hemagglutinin (H) protein (1µg/ml) 
(11) or cat serum samples at a dilution of 1:1000. Samples were kept at room 
temperature overnight. After two washing steps using Tween wash buffer 
(150 mM NaCl, 0.05% Tween 20, pH 7.4) the strips were incubated for 2 h 
with the secondary antibody (peroxidase-conjugated rabbit anti-mouse IgG or 
goat anti-cat IgG, Jackson ImmunoResearch, diluted 1:1000). Following 
another washing step to remove unbound secondary antibody conjugate, 4-
chloro-1-naphtol was applied directly to the strips for color development. The 
reaction was stopped after 5 min by adding destilled water. 
 
4.8 Serum neutralization test using CDV strain OP 
Microneutralization assays were performed as previously described (1). 
Briefly, serum samples were heat-inactivated at 56°C for 30 min and 200 µl of 
the ten-fold diluted samples were mixed with 200 µl of a virus suspension 
containing 100 TCID50 of CDV OP. After an incubation of 60 min at 37°C 
100 µl of the mixtures were added in quadruplicate to approximately 80% 
confluent Vero cells in a 96-well plate. Three days after cultivation, the cells 
were examined microscopically for the development of typical cytopathic 
effects. Virus-neutralizing antibody titers were calculated by the Spearman-
Kärber method (15). 
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4.9 Serum neutralization test using CDV strain A75/17 
Serum samples were heat-inactivated at 56°C for 30 min and diluted 
1:25 with cell culture medium. Two hundred and fifty microliters of each 
sample plus 4 „medium only“ controls were mixed with 250 µl of an A75/17 
virus suspension and incubated for 60 min at 37°C. Subsequently, 400 µl of 
these mixtures were given to 106 feline PBMCs in 24 well plates. After 2 hours 
of incubation 600 µl of fresh cell culture medium was added. Supernatants 
were analysed for the presence of CDV-RNA by real time TaqMan RT-PCR on 
days 3 and 6 post-infection (pi). If the Ct value difference of a sample 
compared to the mean Ct value of the 4 „medium only“ control cultures on day 
6 pi was greater than 3, the serum was considered positive for the presence of 
virusneutralizing antibodies. Using serum of 10 SPF cats as a negative control 
the Ct value difference was never greater than 0.6. 
 
4.10 FIV enzyme linked immunosorbent assay and western blot 
Cat serum samples were analysed for the presence of antibodies 
against feline immunodeficiency virus (FIV) using recombinant transmembrane 
antigen in an enzyme linked immunosorbent assay (ELISA) as previously 
described (23). Weak positive results were confirmed by Western blot analysis 
(22). 
 
4.11 Statistical analysis 
To determine whether a relationship between CDV and FIV 
seropositivity existed, we performed contingency table analysis by use of the 
software StatView (Version 5. SAS Institute Inc., Cary, NC). P-values <0.05 
were considered as significant. 
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5 Results 
5.1 Infection of cat PBMC with A75/17 in vitro 
In order to compare the susceptibility of canine and feline PBMCs 
towards CDV, we performed an in vitro infectivity assay using PBMCs of the 
two different species and different virus dilutions. Feline PBMCs were as 
susceptible to CDV infection in vitro as canine PBMCs. Indirect IFA using the 
mAb D110 specific for the N protein revealed only few fluorescent cells on day 
1 pi. However, on day 3 pi most of the canine and feline cells that were 
incubated with the non-diluted virus tested positive in the IFA. The number of 
fluorescent cells was proportional to the virus dose used for inoculation. The 
virulent CDV strain A75/17 replicated readily in both dog and cat PBMCs, 
which was demonstrated by the almost identical viral copies found to be 
present in the supernatant of dog and cat lymphocyte cultures over time (Fig. 
1). The signals obtained by real-time RT-PCR reached comparable cycle 
threshold (Ct) values in canine and feline cell cultures demonstrating that there 
is no significant difference in lymphocyte susceptibility to CDV infection in vitro 
between dog and cat. 
 
5.2 Cloning of feline SLAM 
In view of further functional experiments we decided to isolate, clone 
and sequence the feline lymphocyte signaling molecule. Based on the 
consensus sequences from human, bovine and canine SLAM and using 
degenerated primers we succeeded in amplifying part of the feline SLAM gene 
from feline infected PBMCs. The cloned sequence was 458-bp long. We 
sequenced two independent clones. Both sequences were identical. Identities 
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at the nucleotide and protein level with sequence deposited in the Genbank 
are depicted in Table 1. 
An alignement of feline and canine SLAM amino acid sequence is 
shown in Figure 2. 
 
5.3 Indirect immunofluorescence assay 
We aimed to establish an indirect IFA for the rapid detection of 
antibodies against the N protein of CDV in cat sera. To this end, we 
transfected Vero cells with a plasmid containing the cDNA coding for the 
N protein of CDV strain A75/17. Incubation of the transfected cells with the 
mAb D110 against the N protein showed cytoplasmatic fluorescence in about 
every twentieth cell whereas no fluorescence could be observed in the non-
transfected control cells (Fig. 3). Furthermore, the slides were evaluated using 
CDV-antibody positive samples originating from lions from the Serengeti 
National Park and from CDV vaccinated cats. Of the 10 lion sera, 6 had been 
shown to be seropositive in an earlier serum neutralization assay (29). The 
same 6 samples showed a strong fluorescence when the transfected cells 
were used. The sera of the 2 CDV immunized cats tested negative in the IFA 
before vaccination, but already two weeks after the first immunization, a strong 
fluorescent signal could be observed. From these observations it was 
concluded that CDV-transfected Vero cells can readily be used in an indirect 
IFA for the detection of anti-CDV N protein antibodies. 
 
5.4 Western blot analysis 
To confirm the IFA results by an additional and independent method we 
established a Western blot assay using denatured proteins of CDV strain 
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A75/17 as antigens. Incubation of the Western blot strips with the mAb XI-23 
against the H protein resulted in one sharp band at the molecular weight of 
approximately 70 kDa according to the protein standard (Fig. 4). Several 
bands were found on strips incubated with the anti-N protein antibody D110. 
As previously shown, these bands represent protein degradation products 
(27). The strongest band among them, at the molecular weight of 
approximately 60 kDa, was also found on strips incubated with serum of the 
CDV immunized cats and lions from the Serengeti National Park with clinical 
distemper (Fig. 4). Serum samples that recognized bands at the height of 
those recognized by the mAbs, indicating a reaction with the H and N protein 
of CDV, were considered positive in the Western blot assay. Serum samples 
were diluted 1:1000 in order to eliminate non-specific bands found at lower 
dilutions in sera from SPF cats. 
 
5.5 Detection of antibodies against CDV in domestic cats from 
Switzerland, Spain and the United Arab Emirates 
The main goal of this study was to determine the prevalence of 
antibodies against CDV in domestic cats in different countries and to elucidate 
a possible correlation between seropositivity and clinical signs of disease. Cat 
sera were screened for antibodies against the CDV N protein in a 1:20 dilution 
by immunofluorescence. Samples that tested positive in the IFA were tested 
by Western blot to confirm the results. Only cat sera, which were both 
fluorescent positive and showed the two typical bands on the Western blot 
strips, were considered to be truly seropositive. According to these criteria 2% 
(10/500) of the samples from the Swiss domestic cats were seropositive. 
These samples were additionally analysed for virus neutralizing antibodies 
against the CDV strains OP and A75/17 (Table 2). Of note, there was no 
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correlation between the clinical status of the tested cats and the 
seroprevalence. 
Among the tested cats from Spain 8.2% (8/97) were found to be CDV 
seropositive. Two of these cats had also virus neutralizing antibodies. The 
highest number of seropositive cats existed in Abu Dhabi, United Arab 
Emirates (17/93, 18.3%). But despite clear fluorescent signals and broad 
bands in the Western blot, none of these cats had virusneutralizing antibodies. 
Additional information about the presence of antibodies against different 
viruses as feline leukemia virus, feline immunodeficiency virus, feline corona 
virus, feline herpes virus and feline calici virus existed for the samples from 
Abu Dhabi. Remarkably many cats that were CDV seropositive had also 
antibodies against FIV. Therefore, serum samples from Switzerland and Spain 
were also analysed for the presence of FIV-specific antibodies. The number of 
FIV seropositive animals in Switzerland was too low for an analysis. Among 
the 25 CDV seropositive sera from Spain and the United Arab Emirates 10 
samples tested positive for the presence of FIV-specific antibodies by enzyme-
linked immunosorbent assay and Western blotting. To determine whether a 
correlation between FIV and CDV seropositivity existed, we performed a 
contingency table analysis. The proportion of CDV seropositive cats was 
higher in the FIV seropositive population (0.36) than in the FIV seronegative 
population (0.09). The difference in proportions was significant, when chi-
square analysis was performed, χ2(1, N=190)=14.622, P=0.0001. 
 
5.6 Detection of antibodies against CDV in captive large felids from 
European zoos 
In contrast to CDV infection in domestic cats, CDV infection in lions and 
tigers is well-known. However, there are only few data about the CDV 
seroprevalence in captive large felids. The CDV-seropositive rate in the 72 
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captive large felids in Swiss, Austrian and German zoos was 9.7%. Two tigers, 
2 ligers and 3 clouded leopards which, to our knowledge, had never been 
immunized against CDV were found to be seropositive. The 2 ligers were also 
positive in the serum neutralization assays. FIV-specific antibodies were found 
in 11.1% of the captive large felids. However, none of the CDV-positive 
animals tested positive for the presence of antibodies to FIV. 
 
6 Discussion 
Since the outbreak of clinical distemper in the Serengeti lion population 
in 1994, it is widely accepted that also felids can be affected by CDV infection. 
However, despite the huge population size of domestic cats and their close 
contact to domestic dogs, there is only limited information on CDV infection in 
this species. Experimentally infected SPF cats in two different experiments 
produced virus neutralizing antibodies and showed no clinical signs. Infectious 
virus was isolated from lymphatic and lung tissues of intranasally infected cats 
between days 5 and 7 pi in one experiment (2), using the Snyder Hill strain for 
infection. In an other experiment, cats were infected intratracheally with CDV 
field strain A92-27/4, an isolate from a diseased leopard, and infective virus 
was isolated from PBMCs between days 1 and 21 pi (18). In both experiments, 
using either a vaccine or a field strain of CDV, infection in domestic cats 
proceeded like infection with an attenuated CDV strain in dogs. The reason for 
this phenomenon is unknown. In our study, we were able to show that CDV 
field strain A75/17 replicated as efficiently in feline PBMCs in vitro as in canine 
PBMCs. There was no obvious difference between the two species in this in 
vitro infectivity assay. Therefore, the difference in the susceptibility to CDV 
infection between dogs and cats does not seem to be caused by any PBMC 
receptor differences. On the contrary, our results indicate the presence of a 
feline signaling lymphocyte activation molecule (SLAM, CD150). SLAM is a 
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membrane glycoprotein found in human beings, monkeys, dogs, cows, rats 
and mice and known to act as a cellular receptor for different morbilliviruses 
(33, 34). It is expressed on activated lymphatic cells and the only known 
receptor for CDV field strains at the moment (30). We were able to sequence a 
458-bp long stretch of the feline SLAM gene with 84% identity to the canine 
sequence. 
Natural CDV infection in domestic cats was demonstrated by the 
presence of virus neutralizing antibodies in cat sera collected in Asian 
countries (19). The seroprevalence was dependant on the region studied and 
on exposure to dogs. In our study, seropositivity was determined by both 
immunofluorescence and Western blot assays. Antibodies of seropositive cats 
reacted with the N protein of CDV strain A75/17 expressed by transfected 
Vero cells used in the IFA and with the denatured N and H protein of A75/17 
on Western blot strips. Several bands representing protein degradation 
products were found on Western blot strips incubated with the mAb D110 
specific for the N protein. In contrast, only one strong band was seen in 
Western blot strips incubated with feline serum samples. This can be 
explained by the much higher concentration of N specific antibodies using the 
mAb compared to the thousandfold diluted cat serum samples. According to 
these criteria, we found a low seroprevalence in domestic cats in Switzerland, 
which can be explained by the low incidence of distemper in dogs in this 
country. Due to dog registration in the local communities and capturing of stray 
dogs by animal welfare organizations, only few feral dogs live in Switzerland. 
In addition, most of the dogs receive at least their first two vaccinations, which 
confer immunity for 3 years (17). This protects dogs during the most critical 
age of 3 to 6 months. In addition, morbilliviruses do not persist in an infectious 
form in the environment. They rely on a constant availability of infected 
shedders and susceptible hosts. Thus, distemper is rarely occurring in the 
Swiss dog population. 
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Serum samples from Switzerland originated from the whole country 
whereas samples from Spain and the United Arab Emirates were collected 
mainly in one region of the country and were therefore less representative. 
Nevertheless, there was a relatively high rate of CDV seropositive cats in 
Spain which could be explained by the large number of feral dogs and the 
relatively low vaccination rate in this country. As a consequence, there are a 
high number of carriers, which keep infectious virus in the population and are 
able to transmit CDV to susceptible hosts. Therefore, CDV is a common cause 
of disease and death in dogs, ferrets, minks and foxes in Spain (21). This is in 
agreement with the results of this study in which we found a relatively high 
CDV seropositive rate in Spanish domestic cats when compared to the 
situation in Switzerland. These results suggest that viral transmission from 
dogs to cats, which was demonstrated in a previous experiment (2), is a 
common event also under natural conditions. This could have been the case in 
one Swiss cat, which was kept in the same household as an acutely infected 
dog that eventually died as a consequence of clinical distemper. This cat 
showed a high antibody titer in the IFA and in the serumneutralization test 
confirming seroconversion to CDV. Interestingly, no antibodies were found in a 
second cat living in the same household, which had even closer contact to the 
dog by sleeping at the same place and eating from the same dish. 
The highest seroprevalence of CDV in cats was observed among the 
samples collected in Abu Dhabi, United Arab Emirates. Of note, there is a low 
proportion of feral dogs due to religious reasons in this country and clinical 
distemper is therefore rarely seen. However, there is an estimated large 
population of feral cats. Two possible reasons could explain the large number 
of CDV seropositive cats in this country. The first is the presence of another 
source of CDV than the dog. As the virus is not very stable in the environment, 
relatively close contact between carrier animals and susceptible hosts is 
necessary. In the absence of dogs, free-ranging small carnivores, such as 
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foxes and martens, are possible carrier candidates and could play an 
important role in the transmission of CDV to feral cats. The second possibility 
relies on the fact that CDV or a closely related virus could circulate in the cat 
population independent of external carriers. In this case, cats would also have 
to shed virus during the acute infection as observed in the dog population. 
This, however, has not been shown yet and therefore remains a speculation. 
There was a lack of virus neutralizing antibodies in most seropositive 
cats in this study. However, the OP vaccinated cats and the Serengeti lions, 
which were infected with a CDV strain closely related to OP (29), all had virus 
neutralizing antibodies against OP. As the CDV field strains are genetically 
distinct from the vaccine strains, we performed a second virus neutralizing 
assay using A75/17, but there was just one additional domestic cat with 
neutralizing antibodies against this field strain. Since wild-type CDV strains 
differ according to geographical distribution and A75/17 was isolated in 
America (32), the lack of virusneutralizing antibodies still can be explained by 
the infection with a different CDV strain or even with another morbillivirus that 
induced the production of cross-reacting antibodies. 
CDV seropositive cats in our study were not at a higher risk of any 
disease than seronegative cats. In addition, no correlation between sex or age 
of the cats and the presence of antibodies against CDV could be found. 
However, the proportion of CDV seropositive cats among the cats from Spain 
and the United Arab Emirates was significantly higher in the FIV seropositive 
population than in the FIV seronegative cats. The reasons for that remain 
unclear. A possible explanation may lie in the fact that several lymphocyte 
populations are activated especially during early FIV infection (20). This could 
lead to an increased expression of SLAM (24) resulting in an increased 
susceptibility to morbillivirus infections. Therefore, FIV and CDV infection may 
be causally related but do not necessarily correlate with clinical signs. Another 
explanation would be a higher susceptibility to CDV infection due to 
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immunosuppression at a late stage of FIV infection. As both FIV and CDV are 
not very stable in the environment similar transmission routes could also 
explain the combined occurrence of FIV and CDV infections. Interestingly, in 
large felids, no correlation between FIV and CDV infection was found. The FIV 
seropositive lions from the Serengeti National Park were neither at a higher 
risk of acquiring CDV infection nor was their mortality higher (28, 29). Studies 
on CDV infected captive large felids in North America and Switzerland did not 
reveal any association of CDV infection with FIV either (4, 26). This could be 
explained by the marked genetic heterogeneity and the completely different 
pathogenicity of the large felid lentiviruses compared to FIV in domestic cats 
(31, 35). The high rate of CDV seropositive captive large felids in European 
zoos observed in our study is in accordance with previous reports (14, 26). 
The source of infection for these captive animals is unknown, but infected free-
ranging small carnivores might play an important role in transmission. 
In conclusion, CDV infection in domestic cats or infection with a related 
morbillivirus seems to occur worldwide. In our study, we showed that the 
seroprevalence in different countries varied from 2% to 18.3% and that dogs 
possibly play an important role in transmitting virus to susceptible cats. 
Additional studies investigating virus shedding by cats will be necessary to 
evaluate the role of cats as carriers. In agreement with previous studies we did 
not find any clinical symptoms that could be related to CDV infection in 
seropositive cats. Future studies on the underlying mechanisms will help for a 
better understanding of the CDV pathogenesis and could lead to new ideas of 
protection possibilities against clinical distemper. Nevertheless, disease 
caused by CDV in domestic cats, especially in FIV seropositive individuals at a 
late stage of infection or in cats with other forms of immune suppression has to 
be considered. 
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FIGURE 1. Infection of dog and cat PBMC with A75/17 in vitro. 
The graph represents the results of a real-time RT-PCR performed using RNA 
isolated from supernatants of infected dog (▲) and cat (■) PBMC and from cell 
culture medium incubated with CDV strain A75/17 without cells (●). The results 
were obtained using a virus dilution of 1:4, but were similar at all other 
dilutions. Non-infected control dog (∆) and cat (□) PBMC resulted in a negative 
signal in the real-time RT-PCR. Results are shown in cycle threshold (Ct) 
values with their respective standard deviation. 
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Cat         LYEQVSTPEIKVLNWTQENGNCSLTLACEVEKGDHVAYSWREETGADPPISANSSHL-HL  60 
Consensus   LYEQVSTPEIKVLNWTQENGNCS  LACEVEKGD V YSW E  G DP I ANSSHL HL 
Dog         LYEQVSTPEIKVLNWTQENGNCSMMLACEVEKGDNVVYSWSEKLGIDPLIPANSSHLLHL  196 
 
Cat         SLGPQHVHNVYVCTVSNPISNHSQTFTPGSVCMPDPPELRPWGLYVGLSSGAVIGVILTL  118 
Consensus   SLGPQHV NVYVCTVSNP SN S  F P S C P     R W LY GL  G   GVIL   
Dog         SLGPQHVNNVYVCTVSNPVSNRSWSFNPWSKCRPESSVPRQWRLYAGLFLGGIVGVILIF  256 
 
Cat         KVAVLLLRRRGKANHYQPTTEAKSLTIYAQVQK  152 
Consensus    V  LLLRRRGK NHY PT E KSLTIYAQVQK 
Dog         EVVLLLLRRRGKTNHYKPTKEEKSLTIYAQVQK  289 
 
 
 
 
FIGURE 2. Alignement of predicted feline SLAM protein sequence with canine 
SLAM. 
 
Comparison of deduced amino acid sequence of feline SLAM (BLASTX 
2.2.13, Matrix (BLOSUM62), Gap costs (Existence: 11; Extension:1) with dog 
amino acid sequence. Dashes (-) show gaps of the feline amino acid 
sequence in comparison to the canine sequence. Consensus shows identical 
amino acids. 
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FIGURE 3. Indirect immunofluorescence assay for detection of antibodies 
specific for the N protein of CDV. 
 
Transfected Vero cells expressing the N protein of CDV strain A75/17 were 
used as antigen. Panels A represent transfected cells incubated with mouse 
monoclonal antibody specific for the N protein and secondary FITC-conjugated 
anti-mouse IgG antibody; panels B represent non-transfected cells incubated 
with the same antibodies as panels A (negative control for transfection); 
panels C and D show transfected cells incubated with serum of either a CDV 
seropositive cat (cat C1 that lived together with a dog with clinical distemper, 
panels C) or a CDV seronegative cat (SPF cat, panels D) and secondary 
FITC-conjugated anti-cat IgG antibody. Cat sera were diluted 1:160. Upper 
panels show the FITC fluorescence, lower panels both the FITC and DAPI 
fluorescence. 
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FIGURE 4. Western blot analysis of felid sera reacting with CDV-specific 
proteins. 
 
lane 1, monoclonal antibody D110 against the N protein; lane 2, monoclonal 
antibody XI-23 against the H protein; lane 3, cat serum before CDV 
immunization; lane 4, cat serum after CDV immunization; lanes 5 and 6, SPF 
cat sera (negative controls); lanes 7-9, representative sera of CDV 
seropositive domestic cats; lane 10, serum of a healthy non-vaccinated captive 
liger from Germany, lane 11, serum of a lion from Tanzania with clinical 
distemper. MW, Molecular weight marker (kDa); C, Control using only 
secondary antibody. 
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TABLE 1. Sequence identities of feline SLAM to other species. 
 
 
Species Dog Cattle Human 
Cotton-
headed 
tamarin 
Mouse Rat 
Accession 
Nr. 
NP_001003084 NP_776609 NP_003028 AAG18445 NP_038758 XP_573513 
A
m
in
o 
ac
id
 
Identities 
to feline 
predicted 
sequence1
72% 68% 66% 64% 54% 53% 
Accession 
Nr. 
AF325357 AF329970 AY0400554 AF302038 AF149791 XP_573513 
N
uc
le
ot
id
e 
Identities 
to feline 
sequence2
84% 77% 80% 79% 71% 70% 
 
1 BLASTX 2.2.13, Matrix (BLOSUM62), Gap costs (Existence: 11; Extension:1) 
2 GCG Bestfit, gap creation penalty (50), gap extension penalty (3) 
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TABLE 2. Comparison of immunofluorescence and western blot with serum 
neutralization test results. 
 
Seropositive samples1 OP virus neutralizing 
antibodies (titer) 
A75/17 virus neutralizing 
antibodies (ct value 
difference) 
Domestic cats     
Switzerland 1/10 (1:269) 2/10 (3.16, 6.98) 
Spain 2/8 (1:80, 1:135) 2/8 (3.15, 8.64) 
UAE 0/17  0/17  
Vaccinated cats 2/2 (1:640, 1:1280) 2/2 (3.89, 4.19) 
Large felids     
Free-ranging lions 
Tanzania 
6/6  (1:320, 1:381, 
1:453, 1:453, 
1:538, 1:538) 
3/6 (3.09, 3.58, 3.86) 
Captive large felids 
Europe 
2/7  (1:640, 1:1280) 2/7 (3.01, 3.45) 
 
1 Seropositivity was determined by an indirect immunofluorescence and a Western blot 
assay. All tested seronegative samples (n=46) were negative in both serum neutralization 
tests and are therefore not included in the table. 
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